Expert Practice Meeting in Lung Cancer
14 Mar 2015
Novotel Amsterdam City, Amsterdam, Netherlands
This educational activity is intended for European medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, pathologists, and other oncology healthcare professionals interested and/or involved in the treatment of patients with NSCLC.
Learning Objectives
After successful completion of this educational activity, participants should be able to:
-
Evaluate lung cancer biomarkers to inform choice of treatment strategy for NSCLC, including optimal methods for tissue sampling, analysis, and evaluation of results
-
Identify the role of immunotherapy in lung cancer, in particular the role of checkpoint inhibition, and evaluate efficacy and safety of these treatments in NSCLC
-
Adopt a multidisciplinary approach for the care of patients with lung cancer
-
Evaluate and incorporate the latest clinical trial data describing the use of chemotherapy and targeted agents in the choice of first-line, second-line, and maintenance therapy in lung cancer
-
Recognise the emerging treatment options for squamous cell NSCLC in order to provide best care for patients with these forms of lung cancer
No items were found.